Adaptimmune Therapeutics Plc Stock Performance
| ADAP Stock | USD 0.66 0.02 3.13% |
The firm shows a Beta (market volatility) of 1.45, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Adaptimmune Therapeutics will likely underperform. At this point, Adaptimmune Therapeutics has a negative expected return of -0.87%. Please make sure to confirm Adaptimmune Therapeutics' standard deviation, kurtosis, period momentum indicator, as well as the relationship between the maximum drawdown and day median price , to decide if Adaptimmune Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Adaptimmune Therapeutics Plc has generated negative risk-adjusted returns adding no value to investors with long positions. Even with conflicting performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Dividend Date 2018-03-30 |
1 | Acquisition by Joanna Brewer of 565416 shares of Adaptimmune Therapeutics at 0.0013 subject to Rule 16b-3 | 08/30/2024 |
2 | Acquisition by John Lunger of 2544432 shares of Adaptimmune Therapeutics at 0.14 subject to Rule 16b-3 | 09/13/2024 |
3 | Adaptimmune Therapeutics plcs top owners are individual investors with percent stake, while 28 percent is held by institutions | 09/25/2024 |
4 | ReCode Announces Two Key Additions to Scientific Advisory Board | 10/01/2024 |
5 | Acquisition by Hegde Priti of 152376 shares of Adaptimmune Therapeutics at 0.11 subject to Rule 16b-3 | 10/11/2024 |
6 | Adaptimmune Therapeutics plc Short Interest Update | 10/16/2024 |
7 | Acquisition by Tayton-martin Helen Katrina of 2544432 shares of Adaptimmune Therapeutics at 0.14 subject to Rule 16b-3 | 10/18/2024 |
8 | Acquisition by Allen Andrew R of 56868 shares of Adaptimmune Therapeutics at 1.78 subject to Rule 16b-3 | 10/21/2024 |
9 | Painful week for retail investors invested in Adaptimmune Therapeutics plc after 11 percent drop, institutions also suffered losses | 10/25/2024 |
10 | Adaptimmune to Participate in Scientific and Medical Conferences this November and December | 11/05/2024 |
11 | Insider Trading | 11/06/2024 |
12 | Adaptimmune Reports Q3 2024 Financial and Business Updates | 11/13/2024 |
13 | Adaptimmune Therapeutics earnings matched, revenue topped estimates | 11/14/2024 |
14 | Europes TCR immunotherapy licensing deals surge 123 percent above US in 2024 | 11/22/2024 |
| Begin Period Cash Flow | 109.6 M |
Adaptimmune |
Adaptimmune Therapeutics Relative Risk vs. Return Landscape
If you would invest 124.00 in Adaptimmune Therapeutics Plc on August 27, 2024 and sell it today you would lose (58.00) from holding Adaptimmune Therapeutics Plc or give up 46.77% of portfolio value over 90 days. Adaptimmune Therapeutics Plc is currently does not generate positive expected returns and assumes 4.5066% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Adaptimmune, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Adaptimmune Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Adaptimmune Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Adaptimmune Therapeutics Plc, and traders can use it to determine the average amount a Adaptimmune Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1939
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ADAP |
Estimated Market Risk
| 4.51 actual daily | 40 60% of assets are more volatile |
Expected Return
| -0.87 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Adaptimmune Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Adaptimmune Therapeutics by adding Adaptimmune Therapeutics to a well-diversified portfolio.
Adaptimmune Therapeutics Fundamentals Growth
Adaptimmune Stock prices reflect investors' perceptions of the future prospects and financial health of Adaptimmune Therapeutics, and Adaptimmune Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Adaptimmune Stock performance.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.51) % | ||||
| Operating Margin | 0.54 % | ||||
| Current Valuation | 57.7 M | ||||
| Shares Outstanding | 255.88 M | ||||
| Price To Earning | (7.73) X | ||||
| Price To Book | 2.12 X | ||||
| Price To Sales | 1.20 X | ||||
| Revenue | 60.28 M | ||||
| Gross Profit | (100.58 M) | ||||
| EBITDA | (128.2 M) | ||||
| Net Income | (113.87 M) | ||||
| Cash And Equivalents | 199.67 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 25.23 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 4.00 X | ||||
| Book Value Per Share | 0.17 X | ||||
| Cash Flow From Operations | (140.88 M) | ||||
| Earnings Per Share | (0.17) X | ||||
| Market Capitalization | 169.29 M | ||||
| Total Asset | 282.62 M | ||||
| Retained Earnings | (1.02 B) | ||||
| Working Capital | 134.76 M | ||||
| Current Asset | 199.54 M | ||||
| Current Liabilities | 22.66 M | ||||
About Adaptimmune Therapeutics Performance
Assessing Adaptimmune Therapeutics' fundamental ratios provides investors with valuable insights into Adaptimmune Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Adaptimmune Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 4.20 | 5.47 | |
| Return On Tangible Assets | (0.40) | (0.42) | |
| Return On Capital Employed | (0.66) | (0.69) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (2.88) | (2.74) |
Things to note about Adaptimmune Therapeutics performance evaluation
Checking the ongoing alerts about Adaptimmune Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Adaptimmune Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Adaptimmune Therapeutics generated a negative expected return over the last 90 days | |
| Adaptimmune Therapeutics has some characteristics of a very speculative penny stock | |
| Adaptimmune Therapeutics has high historical volatility and very poor performance | |
| Adaptimmune Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 60.28 M. Net Loss for the year was (113.87 M) with loss before overhead, payroll, taxes, and interest of (100.58 M). | |
| Adaptimmune Therapeutics Plc currently holds about 199.67 M in cash with (140.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 60.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Europes TCR immunotherapy licensing deals surge 123 percent above US in 2024 |
- Analyzing Adaptimmune Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Adaptimmune Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Adaptimmune Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Adaptimmune Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Adaptimmune Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Adaptimmune Therapeutics' stock. These opinions can provide insight into Adaptimmune Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.